Skip to main content

Table 2 Ongoing clinical trials with immune checkpoint inhibitors in first line setting for SCLC

From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Clinical trial ID

Phase

Setting

Regimen

Endpoint

NCT03382561

II

ED-SCLC

CE vs CE plus nivolumab

PFS

NCT02580994 (REACTION)

II

ED-SCLC

CE vs CE plus pembrolizumab

PFS

NCT02934503

II

ED-SCLC

CE plus pembrolizumab +/− RT

PD-L1 changes

NCT03066778 (KEYNOTE-604)

III

ED-SCLC

CE plus pembrolizumab/placebo

PFS

OS

NCT02763579

III

ED-SCLC

CE plus atezolizumab/placebo

PFS

OS

NCT03043872

III

ED-SCLC

CE vs CE plus durvalumab +/−tremelimumab

PFS

OS

NCT02402920

I

LD-SCLC

CE-RT plus pembrolizumab

MTD

  1. ED-SCLC Extensive-stage Disease Small cell lung cancer, CE Cisplatin/Carboplatin plus Etoposide, PFS Progression Free Survival, DLTs Dose-limiting Toxicities, OS Overall Survival, AEs Adverse Events, ORR Overall Response Rate, LD-SCLC Limited-stage Disease Small cell lung cancer, RT Radiotherapy, MTD Maximum Tolerated Dose